UK-headquartered biotech CellCentric has raised $220 million in a Series D financing that will help to fund pivotal trials of oral p300/CBP inhibitor inobrodib in multiple myeloma.

总部位于英国的生物技术公司 CellCentric 在 D 轮融资中筹集了 2.2 亿美元，这笔资金将用于资助口服 p300/CBP 抑制剂 Inobrodib 在多发性骨髓瘤中的关键试验。

The Anglo-US company recently started dosing patients in the phase 2 DOMMINO-1 study of inobrodib in combination with pomalidomide and dexamethasone (InoPd) in heavily pretreated multiple myeloma patients in the UK and US, and is in the planning stages for an international phase 3 trial, DOMMINO-2, before the end of the year..

这家英美公司最近开始在英国和美国对重度预处理的多发性骨髓瘤患者进行 inobrodib 联合泊马度胺和地塞米松（InoPd）的 2 期 DOMMINO-1 研究的患者给药，并计划在今年年底前开展国际 3 期试验 DOMMINO-2。

DOMMINO-2 will also look at the InoPd regimen in relapsed/refractory multiple myeloma. Meanwhile, CellCentric is also exploring combinations of the potentially first-in-class p300/CBP inhibitor with Pfizer's

DOMMINO-2 还将研究 InoPd 方案在复发/难治性多发性骨髓瘤中的应用。同时，CellCentric 也在探索潜在的同类首创 p300/CBP 抑制剂与辉瑞药物的联合使用。

Elrexfio

埃尔雷克菲奥

(elranatamab) and Johnson & Johnson's

(elranatamab) 和强生公司的

Tecvayli

特克韦利

(teclistamab), both BCMAxCD3 bispecific antibodies, which are respectively approved as fifth- and second-line or later therapies for multiple myeloma.

(teclistamab)，均为BCMAxCD3双特异性抗体，分别被批准作为多发性骨髓瘤的五线及二线或更晚治疗药物。

The Series D is the second sizeable financing from a UK biotech this week, coming shortly after

D轮融资是本周英国生物技术公司的第二笔大规模融资，紧随其后的是

Cytospire Therapeutics

赛托斯派尔治疗学

raised $83 million for its T-cell engager pipeline, and adds to the recovery in UK biotech industry investing that has emerged since the start of the year. It also comes around a year after CellCentric closed a $120 million third-round financing, which was

为它的T细胞衔接器管道筹集了8300万美元，并且增加了自今年年初以来出现的英国生物技术行业投资的复苏。这也发生在CellCentric完成1.2亿美元第三轮融资的大约一年后，该融资是

one of the largest

最大的之一

for a UK biotech last year.

去年对于一家英国生物技术公司而言。

The latest cash injection will also be used by CellCentric to expand clinical testing of inobrodib into additional combination and maintenance treatment settings, said the Cambridge and Boston-based biotech in a statement.

剑桥和波士顿的这家生物技术公司在一份声明中表示，CellCentric 还将利用最新的资金注入，将 inobrodib 的临床试验扩展到更多的联合治疗和维持治疗环境中。

Data reported at last year's ASH congress from a phase 2 InoPd dose-optimisation study showed the combination achieved at least a two-fold increase in response rates compared to alternative medicines in patients who had received a median of five earlier lines of therapy.

去年ASH大会上报告的来自InoPd剂量优化研究II期数据显示，该组合疗法在既往接受过中位五线治疗的患者中，应答率至少是其他药物的两倍。

The financing was led by specialist investor Venrock Healthcare Capital Partners, with participation from a strong syndicate of new and existing investors that included Fidelity Management & Research Co, Sofinnova Partners, HBM Healthcare, RA Capital Management, Forbion, Pfizer, Avego BioScience Capital, and American Cancer Society BrightEdge..

本轮融资由专业投资机构Venrock Healthcare Capital Partners领投，参与融资的还有包括富达管理与研究公司（Fidelity Management & Research Co）、Sofinnova Partners、HBM Healthcare、RA Capital Management、Forbion、辉瑞（Pfizer）、Avego BioScience Capital和美国癌症协会BrightEdge在内的新老投资者组成的强大财团。

'We are thrilled to have the support of top-tier investors who believe in inobrodib's potential to address a critical need in multiple myeloma, notably after bispecific T cell engager or anti-BCMA therapies,' said CellCentric's chief executive, Will West, noting this is a 'significant and growing unmet need.'.

“我们非常高兴能够获得顶级投资者的支持，他们相信inobrodib在多发性骨髓瘤领域解决关键需求的潜力，尤其是在双特异性T细胞接合器或抗BCMA疗法之后，”CellCentric首席执行官威尔·韦斯特表示，并指出这是一个“重要且日益增长的未满足需求”。

He added: 'Inobrodib is a new modality and a potential fresh option for patients that is orally administered. Fuelled by this funding, we are well-positioned to complete registration enabling studies for the all-oral triplet and advance our progress toward delivering a transformative treatment.'

他补充说：“Inobrodib 是一种新的治疗方式，也是患者潜在的新选择，可以口服。在此次资金的支持下，我们有能力完成针对全口服三联疗法的注册研究，并推进我们向提供变革性治疗的目标迈进。”